What is the transition process from IV to SC insulin in the treatment of DKA?
Understand the Problem
The content is discussing the transition from intravenous (IV) insulin to subcutaneous (SC) insulin therapy for treating Diabetic Ketoacidosis (DKA), emphasizing the importance of allowing an overlap to prevent recurrence of DKA.
Answer
Allow a 1-2 hour overlap between stopping IV insulin and starting SC insulin.
The transition from IV to SC insulin in DKA involves allowing an overlap of 1-2 hours between stopping IV insulin and starting SC insulin, except when rapid-acting insulin analogs are used.
Answer for screen readers
The transition from IV to SC insulin in DKA involves allowing an overlap of 1-2 hours between stopping IV insulin and starting SC insulin, except when rapid-acting insulin analogs are used.
More Information
Rapid-acting insulin analogs (Aspart, Glulisine, and Lispro) do not require an overlap period. This ensures a smooth transition and avoids recurrence of DKA.
Tips
A common mistake is not allowing enough overlap time, which can lead to a gap in insulin coverage and potential recurrence of DKA. Adjusting for rapid-acting analogs is also key.
Sources
- Improving Intravenous and Subcutaneous Insulin Overlap During ... - pmc.ncbi.nlm.nih.gov
AI-generated content may contain errors. Please verify critical information
